Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant Bone and Soft Tissue Tumors
1 other identifier
interventional
98
1 country
1
Brief Summary
To verify and evaluate the safety and efficacy of biodegradable magnesium metal clips in the surgical margins of radical surgery for bone and soft tissue malignant tumors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2024
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 21, 2024
CompletedFirst Posted
Study publicly available on registry
August 13, 2024
CompletedStudy Start
First participant enrolled
August 25, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
August 13, 2024
July 1, 2024
2.8 years
July 21, 2024
August 8, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
1-year tumor recurrence rate
Calculate the recurrence rate of the tumor one year after surgery.
1 year
Total drainage volume
Placement of a drainage tube in the surgical area, with postoperative drainage volumes recorded on the first, second, third, and fourth days.
on the first, second, third, and fourth postoperative days.
Secondary Outcomes (4)
Blood magnesium ions levels
at one month and six months after the operation
Serum alanine aminotransferase (ALT)
at one month and six months after the operation
Serum creatinine
at one month and six months after the operation
Estimated glomerular filtration rate (eGFR)
at one month and six months after the operation
Study Arms (2)
Control group
NO INTERVENTIONThe tumor lesion area is exposed using conventional surgery methods, and the tumor segment is resected according to the principles of tumor-free operation. Electrocautery and suture ligation are used to handle the tumor bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
Magnesium metal closure clips
EXPERIMENTALThe tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
Interventions
The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
Eligibility Criteria
You may qualify if:
- Participants must be of either gender, aged between 18 and 65 years;
- Diagnosis must be confirmed pathologically as osteosarcoma, synovial sarcoma, liposarcoma, or other bone and soft tissue sarcomas;
- Must have undergone standard chemotherapy and require en bloc resection;
- Participants must voluntarily enroll and sign an informed consent form; willing to closely cooperate with the physician to comply with all study requirements, including participation in all follow-up and assessments.
You may not qualify if:
- Severe dysfunction of the heart, liver, kidney, lung, or brain.
- Pregnant women or women who are breastfeeding.
- History of autoimmune disease, HIV infection, history of immunosuppressive disorder, or currently taking immunosuppressive drugs.
- History of syphilis (Treponema pallidum), active infection with hepatitis B or C, and positive for verified antigens.
- Participation in any other clinical study currently or within 3 months prior to the screening visit.
- Patients have any other conditions that the researcher deems unsuitable for the study. Age is between 18 to 75 years old.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Guangdong provincial people's hospital
Guangzhou, Guangdong, 516008, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 21, 2024
First Posted
August 13, 2024
Study Start
August 25, 2024
Primary Completion (Estimated)
June 30, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
August 13, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will not share
Researchers can request access from the corresponding author upon reasonable inquiry.